# US 11,439,651 B2 · Nasal spray composition for COVID-19 and SARS and method of forming the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,439,651 B2 - Document ID: US11439651B2 - Status: Granted - Kind: B2 - Application number: 17/374,819 - Filed: 2021-07-13 - Published: 2022-04-21 - Granted: 2022-09-13 - Earliest claimed: 2020-10-18 - Assignees: CoFix-RX, LLC - Applicants: CoFix-RX, LLC - Inventors: Ravi Hedni; Karen Raehtz; Dennis G Kaiser; Andrew Krause - Web page: https://patentgrep.com/patent/US11439651B2 ## CPC - A61K 9/0043: {Nose} - A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3 - A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)} - A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems - A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2 - A61K 33/18: Iodine; Compounds thereof - A61K 47/02: Inorganic compounds - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A nasal spray solution of the present invention includes a Povidone iodine solution; a Vitamin D liquid, Polysorbate 80 nf, Xylitol NF, water sterile, Sodium hydroxide 10% solution, and Polysaccharide 1% solution, wherein 1% solution further includes a gellan gum and a carrageenan, used as carriers to deliver liquids to cells of human and act as entrapment within a polymeric coating to block virus uptake into the cells, inactivate the virus, and protect a lining of an upper respiratory pathways against COVID-19 and SARS. ## Claims ### Claim 1 A liquid nasal spray composition to treat a viral respiratory infectious disease, the nasal spray composition comprising: a first component comprising an iodophor solution that includes iodine and povidone; a second component comprising a liquid form of Vitamin D; a third component comprising Polysorbate 80 nf; a fourth component comprising Xylitol NF; a fifth component comprising sterile water; a sixth component comprising a 10% solution of sodium hydroxide; and a seventh component comprising a 1% solution of Polysaccharide; the 1% solution of Polysaccharide including a gellan gum and a carrageenan; wherein the first, second, third, fourth, sixth and seventh components are added and dissolved in the fifth component to produce the liquid nasal spray composition. ### Claim 2 (depends on 1) The liquid nasal spray composition of claim 1, wherein the first component is a Povidone-iodine solution, wherein at least 12.5 ml of the Povidone-iodine solution is used to produce the liquid nasal spray composition. ### Claim 3 (depends on 1) The liquid nasal spray composition of claim 1, wherein at least 1 gm of the liquid form of Vitamin D is used to produce the liquid nasal spray composition. ### Claim 4 (depends on 3) The liquid nasal spray composition of claim 3, wherein at least 1 ml of the Polysorbate 80 nf is used to produce the liquid nasal spray composition. ### Claim 5 (depends on 1) The liquid nasal spray composition of claim 1, wherein at least 5 gm of the Xylitol NF is used to produce the liquid nasal spray composition. ### Claim 6 (depends on 1) The liquid nasal spray composition of claim 1, wherein at least 7 GTTs (drops) of the 10% solution of sodium hydroxide are used to produce the liquid nasal spray composition. ### Claim 7 (depends on 1) The liquid nasal spray composition of claim 1, wherein at least 20 ml of the 1% solution of Polysaccharide are used to produce the liquid nasal spray composition. ### Claim 8 (depends on 7) The liquid nasal spray composition of claim 7, wherein 0.15 gm of the gellan gum and 0.05 gm of the carrageenan are used to produce the 1% solution of Polysaccharide. ### Claim 9 (depends on 7) The liquid nasal spray composition of claim 7, wherein 0.05 gm of the gellan gum and 0.15 gm of the carrageenan are used to produce the 1% solution of Polysaccharide. ### Claim 10 A liquid nasal spray composition to treat a viral respiratory infectious disease, the nasal spray composition comprising: a first component comprising an iodophor solution in an amount of 12.5 ml, wherein the iodophor solution includes iodine and povidone; a second component comprising a liquid form of Vitamin D in an amount of 1 gram; a third component comprising Polysorbate 80 nf in an amount of 1 ml; a fourth component comprising Xylitol NF in an amount of 5 grams; a fifth component comprising sterile water in an amount of 100 ml; a sixth component comprising a 10% solution of sodium hydroxide in an amount of 7 GTTs (drops); and a seventh component comprising a 1% solution of Polysaccharide in an amount of 20 ml, wherein the 1% solution of Polysaccharide includes a gellan gum and a carrageenan; wherein the first, second, third, fourth, sixth and seventh components are added and dissolved in the fifth component to produce the liquid nasal spray composition. ### Claim 11 (depends on 10) The liquid nasal spray composition of claim 10, wherein 0.15 grams of the gellan gum and 0.05 gm of the carrageenan are used to produce the 1% solution of Polysaccharide. ### Claim 12 (depends on 10) The liquid nasal spray composition of claim 10, wherein 0.05 grams of the gellan gum and 0.15 gm of the carrageenan are used to produce the 1% solution of Polysaccharide.